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A scientist must always be absolutely like a child. If he sees a thing, he must
say that he sees it, whether it was what he thought he was going to see or not.
See first, think later, then test. But always see first. Otherwise you will only
see what you are expecting. Most scientists forget that.
—Douglas Adams
So Long, and Thanks for All the Fish
The overwhelming majority of readers of this editorial will be car-diothoracic surgeons. Many may have returned from the operatingroom knowing they have performed a technically good cardiacprocedure and can confidently tell the patient that all went very welland an excellent result is anticipated.
Before leaving the hospital for the day, the reader would like to confirm the
patient is warm to the periphery, passing adequate volumes of urine, requiring no
inotropic drugs, is extubated, and is talking rationally and coherently with his or her
loved ones. A small minority of the patients with no obvious risk or preoperative
problems will not have this recovery pattern. These patients may be slow to rewarm,
possibly with a mild acidosis. They may require low doses of inotropic agents,
regular diuretics to maintain an adequate urine output, and their oxygen transfer may
not be quite good enough to allow weaning from the ventilator. This response is
never anticipated and is rarely fatal, but it slows the progress of the patient’s
recovery and is usually attributed to an abnormal inflammatory response to the
operation.
The term systemic implies that the normally localized and integrated hemostatic
and immune response to trauma or invasion1 has become unleashed on the whole
body. The extracorporeal system (and sometimes its driver) usually takes the blame
for this!
The definition of systemic inflammatory response syndrome (SIRS) includes
tachycardia and tachypnea with changes in temperature and white blood cell count.2
However, this definition is not altogether helpful in patients having cardiovascular
surgery since most patients will be receiving not only positive-pressure ventilation
(removing the respiratory component of the definition) but also -adrenoceptor
blocking agents (reducing confidence in the definition of tachycardia). Many pa-
tients after cardiac surgery will have temperatures approaching 38°C and white
counts in the 11 to 12  109/L range. However, if the patient is orientated, warm,
well-perfused, and passing adequate volumes of urine, he or she is considered as
following a normal postoperative course. It is axiomatic that if you, the reader, had
leukocytosis, a mild pyrexia, and possibly a degree of nausea then you would
consider yourself abnormal, if not downright ill.
Herein lies the crux of the matter. How can we distinguish the normal “physi-
ologic” response from an abnormal, possibly pathologic process when the variable
is likely on a continuum? The way this has been largely approached in the past is
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to ignore the clinical signs and symptoms and simply pub-
lish the biochemical data showing a benefit, or not, of the
therapeutic approach under investigation.
Starting with the seminal work of the team in Alabama,3
there has been considerable progress in identifying and
documenting changes in putative mediators of an “abnor-
mal” response. The panoply of initiators, amplifiers, and
effectors of the inflammatory response has in turn become
the focus of attention of the SIRS sleuth. As a consequence,
there is a constant supply of manuscripts supporting or
refuting a particular maneuver as having a major impact on
the inflammatory response.
In this issue of the Journal, Schmartz and colleagues4
report a study that failed to demonstrate any effects of
aprotinin on plasma concentrations of certain cytokine and
complement fragments. The authors conclude that “aproti-
nin . . . has no significant influence on the systemic inflam-
matory response, as assessed by the mediators measured.”
This raises a number of questions related to the potential
of this kind of study in aiding our understanding of adverse
outcomes related to cardiovascular surgery and the effects
of interventions on these unwanted events.
A critical appraisal of this approach needs to address
many issues, and only three will be discussed here. First, is
there evidence to show the modern extracorporeal system is
the primary and singular initiator of the problem? Second,
what clinically useful information is obtained by knowing
the absolute values of the chosen mediators alone? Finally,
what do we want a therapeutic intervention to achieve in
relation to this abnormal biochemistry?
Is There Epidemiologic Evidence That
Extracorporeal Systems Enhance Adverse Outcome?
Large-scale epidemiologic studies have failed to show time
of bypass (90-120 minutes) as a specific or independent
risk factor for the likelihood of dying,5 having respiratory,6
renal,7 or abdominal complications,8 or having a deep ster-
nal wound infection.9 These studies encompass nearly
100,000 procedures.
Further evidence that supports the notion that extracor-
poreal circulation alone is not the initiator of subsequent
problems comes from novel studies in which coronary sur-
gery was done without bypass. As an example, Hernandez
and colleagues10 reported on 7867 patients having myocar-
dial revascularization of whom 1741 were operated on
without bypass. Results for mortality and morbidity (apart
from incidence of atrial fibrillation) were not different be-
tween management strategies. Taken together, the epidemi-
ologic data do not support the concept of extracorporeal
circulation as the principal villain of the piece but suggest
that bypass is safe for the majority of patients.
However, this conclusion does not exclude the possibil-
ity that patients who do less well have an exaggerated
response to the period of surgery and bypass. There is
certainly evidence for great variability in the response of the
fibrinolytic system to surgery and bypass and the response
of individuals to a given inflammatory stimulus.11 The ma-
jor research challenge in the sphere of the inappropriate
inflammatory response remains the identification of those
factors (whether genotypic or phenotypic) contributing to
this increased susceptibility. In the article under discussion,
a patient had excess endotoxin in the plasma, but without
detrimental effect. Does this observation imply that endo-
toxemia alone is not pivotal in the genesis of an unwanted
outcome?
Is There Consistent Evidence That a Specific
Mediator Is Causally Associated With Adverse
Outcome?
The earliest villain in the bypass-related inflammatory re-
sponse was suggested as activation of complement.3 Al-
though these early studies showed convincing evidence for
the role of active fragments in adverse outcomes, activation
of complement has now been superseded in the literature by
other (more recently discovered) markers. The trend away
from the role of complement activation may simply reflect
that the modern bypass system does not induce such activ-
ity. For example, the study by Schmartz and associates
shows no change in activated fragments of C3 or C5 (Ar-
ticle Table 1) and a decrease in C4 activation (Article Figure
2) with the extracorporeal system they used.
Continuing research searching for the mediator of the
bypass-related inflammatory response has produced a vast
amount of biochemical data on an array of potential culprits.
Cytokines are the principal inflammatory marker re-
ported by Schmartz and colleagues.
Whereas, at low concentrations, cytokines seem to be
essential for optimal function of the defense and repair
systems of the body, the higher concentrations of cytokines
measured in association with sepsis, trauma, and heart sur-
gery are singled out as deleterious. The protagonists of this
belief suggest modulating this response will be of benefit to
the patient. The question therefore is whether the evidence
consistently supports this notion.
What Should We Measure?
More than 140 cytokines and chemokines have been recog-
nized in nature. Indeed, one manufacturer of test kits has
cytokines, chemokines, and growth factors organized into a
“periodic table” on the basis of their producing and target
cell. This makes the choice of which “culprit” to measure
somewhat of a lottery.
The multifaceted activity of tumor necrosis factor (TNF)
(and possibly the fact that the kit for measurement in blood
was one of the first commercially available!) makes this a
focal target for investigation. Unfortunately, there are as
many studies that show TNF concentrations rise in associ-
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ation with heart surgery as there are those failing to dem-
onstrate this effect. This lack of consistent response to a
massive and totally unphysiologic stimulus, such as a period
of extracorporeal circulation, suggests that TNF alone is not
pivotal to the genesis of an adverse outcome and may be a
poor marker for such an outcome.
When Should We Measure It?
In addition to whether a response is present or absent, the
timing of that response must be considered. The current
study by Schmartz suggests the peak in interleukin 8 (IL-8)
concentration is some 4 hours after bypass. This timing is
supported by the data of Paugam and colleagues12 after
normothermic bypass. However, the majority of studies
have measured the peak in IL-8 concentration at the end of
surgery or shortly after the release of the aortic crossclamp.
In the search for causal relationships between inflammatory
markers and outcome, this disparity suggests that a peak or
trough can be easily missed.
Does a Rise in a Proinflammatory or Fall in
Antiinflammatory Cytokine Always Predict or Produce
an Adverse Outcome?
A National Library of Medicine database search flags over
1500 publications on the topic of cytokines and heart sur-
gery. Only a handful of these relate their data to an index of
patient outcome. The data presented in this issue are also not
overwhelming in demonstrating a causal relationship be-
tween a rise in concentration of a specific cytokine and an
adverse outcome. The literature from a more general prac-
tice is also not comprehensive, even with a relatively loose
definition of SIRS. Antonelli13 reviewed 89 clinical papers
published between 1993 and 1997 on the role of cytokines
during sepsis and other inflammatory reactions. Cytokines
were analyzed in more than 5000 patients. Fifty (62%) of
the 80 studies that investigated a correlation between cyto-
kine concentration and outcome found the concentrations of
cytokines did not predict death. The rest of the 30 (48%)
investigations depicted an inhomogeneous picture: even
though 27 studies evidenced higher levels of cytokines in
nonsurvivors, 3 studies found the opposite.
It is becoming increasingly apparent that the more-is-
worse therefore less-is-better thinking may not be appropri-
ate in all circumstances. In severe inflammatory states, such
as found with septicemia and meningococcal disease, in-
creased mortality is associate with a lack of TNF response
and an exaggerated IL-10 effect.14,15 This pattern has also
been shown in a separate study of 464 consecutive patients
admitted to the hospital with fever (38.2°C).16 Concen-
trations of IL-10 were significantly higher in the blood of
the 33 patients who died compared with that of survivors.
These data suggest that interventions intended to suppress
the “proinflammatory” (such as TNF) and augment the
“anti-inflammatory” (eg, IL-10) response may not have the
intended effect on outcome. It is apparent that any change,
or lack of it, in a particular cytokine concentration is not
always a good marker of an adverse outcome or disease in
the patient. This leads to the final question raised by the
study by Schmartz and colleagues.
What Do We Want a Therapeutic Intervention to
Achieve and How Can This Be Related to Abnormal
Biochemistry?
The holy grail of the SIRS sleuth is to find a way to block
or inhibit the “badness,” thereby allowing good to prevail.
Reducing the biologic activities of IL-1 and TNF has been
accomplished by several different, but highly specific, strat-
egies, which involve neutralizing antibodies, soluble recep-
tors, and receptor antagonists. Thus far, attempts to block
IL-1 or TNF have been spectacularly unsuccessful in human
beings with sepsis. Agents such as TNF-neutralizing anti-
bodies, soluble TNF receptors, and IL-1 receptor antagonist
have been infused into more than 10,000 patients in double-
blind, placebo-controlled trials. Although there has been a
consistent small increase (2%-3%) in 28-day survivals with
anticytokine therapy, the effect has not reached statistical
significance.17
In contrast, a recent meta-analysis showed that patients
having heart surgery who received high-dose aprotinin ther-
apy had a significant, 2-fold reduction in mortality com-
pared with patients in the placebo or control arm of the
studies examined.18 The exact reason why the use of apro-
tinin therapy is associated with a reduced mortality is cur-
rently opaque. Aprotinin has many potential benefits in
terms of modulating the inflammatory response,19,20 but
these are not consistently reported and may be dependent on
dose.
The confusion surrounding the role of the panoply of
biochemical markers in an adverse outcome is not related
only to cytokine responses. Similar arguments can be made
for virtually all of the “inflammatory markers” reported in
the literature and apply to aprotinin as well. For example, in
a study investigating the influence of aprotinin on oxidant
stress and neutrophil cytotoxicity using a cell culture sys-
tem, decrease in neutrophil-associated cell death was ob-
served with aprotinin but neutrophil respiratory burst, re-
flecting neutrophil oxidant output, was enhanced by this
intervention.21 These data can be used by the protagonists of
aprotinin therapy to show a benefit (reduced toxicity) or by
the antagonists to show a potentially deleterious effect (in-
creased oxidant stress).
Where can we go from here? The first logical step is to
persuade investigators to stop considering biochemistry in
isolation. If the biochemistry is not in some way related to
a simple outcome measure, is it really of any clinical, as
opposed to intellectual interest? An important and as yet not
clearly defined question is, what are the clinically relevant
end points? The obvious suggestion is a patient in a state
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that makes the responsible physician feel comfortable. If the
patient is warm, passing urine, requiring no inotropic drugs,
breathing spontaneously without distress, and talking ratio-
nally and coherently, does it matter that he or she has a
raised “something we have an assay for and can measure?”
So far, the isolated biochemical approach has not proved of
any obvious benefit in helping us predict or understand
nonfatal complications. Is it time to have a rethink on the
strategy of investigating potential interventions or markers
by first defining whether they are associated with improve-
ments or worsening of patient outcomes?
The 50th anniversary of the successful use of the heart-
lung machine will be in May of 2003. Many lives have been
saved and their quality improved because of this innovation;
some have also been lost or the quality reduced. It may be
wishful thinking, but by this anniversary it should not be
beyond the clinical and scientific communities involved in
cardiothoracic surgery to decide on a core group of patient-
oriented end points to allow us to define an appropriate or
inappropriate outcome. These criteria can then be used by
all investigators to ensure that their studies and data can be
related to the patient in addition to the test tube. The
suggestion that the patient is warm to the periphery, passing
adequate volumes of urine, requiring no inotropic agents,
and is extubated and talking rationally and coherently
within a period of time from the end of surgery is what
every clinician anticipates for the patient and therefore
seems a good place to start.
References
1. Royston D. The evolution of coagulation and inflammation. In: Spiess
BD, editor. The relationship between coagulation, inflammation and
the endothelium-A pyramid towards outcome. A Society of Cardio-
vascular Anesthesiologists monograph. Philadelphia: Lippincott Wil-
liams & Wilkins; 2000. p 1-30.
2. Muckart DJ, Bhagwanjee S. American College of Chest Physicians/
Society of Critical Care Medicine Consensus Conference. Definitions
of the systemic inflammatory response syndrome and allied disorders
in relation to critically injured patients. Crit Care Med. 1997;25:1789-
95.
3. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE,
Pacifico AD. Complement and the damaging effects of cardiopulmo-
nary bypass. J Thorac Cardiovasc Surg. 1983;86:845-57.
4. Schmartz D, Tabardel Y, Preiser J-C, Barvais L, d’Hollander A,
Duchateau J, et al. Does aprotinin influence the inflammatory response
to cardiopulmonary bypass in patients? J Thorac Cardiovasc Surg.
2003;125:184-90.
5. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C,
Baudet E, et al. Risk factors and outcome in European cardiac surgery:
analysis of the EuroSCORE multinational database of 19030 patients.
Eur J Cardiothorac Surg. 1999;15:816-23.
6. Christenson JT, Aeberhard JM, Badel P, Pepcak F, Maurice J, Simonet
F, et al. Adult respiratory distress syndrome after cardiac surgery.
Cardiovasc Surg 1996;4:15-21.
7. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. In-
dependent association between acute renal failure and mortality fol-
lowing cardiac surgery. Am J Med. 1998;104:343-8.
8. Tsiotos GG, Mullany CJ, Zietlow S, van Heerden JA. Abdominal
complications following cardiac surgery. Am J Surg. 1994;167:553-7.
9. Stahle E, Tammelin A, Bergstrom R, Hambreus A, Nystrom SO,
Hansson HE. Sternal wound complications: incidence, microbiology
and risk factors. Eur J Cardiothorac Surg. 1997;11:1146-53.
10. Hernandez F, Cohn WE, Baribeau YR, Tryzelaar JF, Charlesworth
DC, Clough RA, et al. In-hospital outcomes of off-pump versus
on-pump coronary artery bypass procedures: a multicenter experience.
Ann Thorac Surg. 2001;72(5):1528-34.
11. Chandler WL, Fitch JC, Wall MH, Verrier ED, Cochran RP, Soltow
LO, et al. Individual variations in the fibrinolytic response during and
after cardiopulmonary bypass. Thromb Haemost. 1995;74:1293-7.
12. Paugam C, Chollet-Martin S, Dehoux M, Chatel D, Brient N, Des-
monts JM, et al. Neutrophil expression of CD11b/CD18 and IL-8
secretion during normothermic cardiopulmonary bypass. J Cardiotho-
rac Vasc Anesth. 1997;11:575-9.
13. Antonelli M. Sepsis and septic shock: pro-inflammatory or anti-in-
flammatory state? J Chemother. 1999;11:536-40.
14. Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A. High
levels of interleukin 10 in serum are associated with fatality in me-
ningococcal disease. Infect Immunol. 1995;63:2109-12.
15. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij
CL, Boomsma DI, et al. Genetic influence on cytokine production and
fatal meningococcal disease. Lancet. 1997;349:170-3.
16. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K,
Frolich M. Anti-inflammatory cytokine profile and mortality in febrile
patients. Lancet. 1998;351:950-3.
17. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118:503-8.
18. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briet E,
et al. Pharmacological strategies to decrease excessive blood loss in
cardiac surgery: a meta-analysis of clinically relevant endpoints. Lan-
cet. 1999;354:1940-7.
19. Royston D. Serine protease inhibition prevents both cellular and
humoral responses to cardiopulmonary bypass. J Cardiovasc Phar-
macol. 1996;27(Suppl 1):S42-9.
20. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory re-
sponse after cardiopulmonary bypass. Ann Thorac Surg. 2001;71:745-
54.
21. Wang JH, Redmond HP, Watson RW, Duggan S, McCarthy J, Barry
M, et al. Mechanisms involved in the induction of human endothelial
cell necrosis. Cell Immunol. 1996;168:91-9.
Royston, Kovesi, Marczin Editorials
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 1 35
ED
IT
O
RI
A
L
